Identifying the optimal dose of ritonavir in the treatment of malignancies

Metabolic Brain Disease

Volumn 29, Issue 2, 2014, Pages 533-540

  Moawad, Emad Y ^a  

^a Ain Shams University   (Egypt)

Author keywords

Apoptosis; Histologic grade; In vitro cell proliferation assay; Nude mouse tumor models

Indexed keywords

RITONAVIR; ANALGESIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG IDENTIFICATION; DRUG RESISTANCE; ENERGY; ENERGY YIELD; FEMALE; GROWTH CURVE; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; THYMOMA CELL LINE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; C57BL MOUSE; DOSE RESPONSE; DRUG SCREENING; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALIA; MUS; MUS MUSCULUS;

ANALGESICS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; RITONAVIR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901587133     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-013-9448-5     Document Type: Article

References (35)

1. Andre P, Groettrup M, Klenerman P et al (1998) An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A 95:13120-13124 (Pubitemid 28509534)
2. Barbalace K (2011) Periodic table of elements - H-Hydrogen. EnvironmentalChemistry.com. 1995-2011. Accessed on-line: 12/21/2011 http://EnvironmentalChemistry.com/yogi/periodic/H-pg2.html
3. Bocchini V, Casalone R, Collini P, Rebel G, Lo Curto F (1991) Changes in glial fibrillary acidic protein and karyotype during culturing of two cell lines established fromhuman glioblastoma multiforme. Cell Tissue Res 265:73-81
4. Bower M, Fox P, Fife K et al (1999) Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 13:2105-2111 (Pubitemid 29509588)
5. Collier AC (1996) Efficacy of combination antiretroviral therapy. Adv Exp Med Biol 394:355-372
6. Collier AC, Coombs RW, Schoenfeld DA et al (1996) Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 334:1011-1017 (Pubitemid 26124452)
7. Cornetta K, Moore A, Johannessohn M, Sledge GW (1994) Clonal dominance detected in metastases but not primary tumors of retrovirally marked human breast carcinoma injected into nude mice. Clin Exp Metastasis 12:3-12 (Pubitemid 24062175)
8. Gaedicke S, Firat-Geier E, Constantiniu O et al (2002) Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 62:6901-6908 (Pubitemid 35424079)
9. Goldberg AL, Rock K (2002) Not just research tools - proteasome inhibitors offer therapeutic promise. Nat Med 8:338-340 (Pubitemid 34407027)
10. Helbig G, Christopherson KW II, Bhat-Nakshatri P et al (2003) NF-κB promotes breast cancer cellmigration andmetastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278:21631-21638 (Pubitemid 36792563)
11. Kyriazis AP, Kyriazis AA, Scarpelli DG, Fogh J, Rao MS, Lepera R (1982) Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics. Am J Pathol 106:250-260 (Pubitemid 12172165)
12. Laurent N, de Bouard S, Guillamo JS et al (2004) Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol Cancer Ther 3:129-136 (Pubitemid 39193687)
13. Levitz SM (1998) Improvement in CD4- cell counts despite persistently detectable HIV load. N Engl J Med 338:1074-1075
14. Moawad E (2010) Isolated system towards a successful radiotherapy treatment. Nucl Med Mol Imaging 44:123-136
15. Moawad EY (2011) Radiotherapy and risks of tumor regrowth or inducing second cancer. Cancer Nanotechnol 2:81-93
16. Moawad EY (2012) Pathologic cancer staging by measuring cell growth energy, basic science and technology. 18:04 WCIO. doi:10.1016/j.jvir.2012.04.029
17. Moawad EY (2012b) Clinical and pathological staging of the cancer at the nanoscale. Cancer Nano 3:37-46
18. Moawad EY (2012c) Reconciliation between the clinical and pathological staging of cancer. Comp Clin Pathol. doi:10.1007/s00580-012-1603-6
19. Moawad EY (2012d) Optimizing bioethanol production through regulating yeast growth energy. Syst Synth Biol 6:61-68
20. Moawad EY (2013a) Administering the optimum dose of L-Arginine in regional tumor therapy. Indian J Clin Biochem. doi:10.1007/s12291-013-0379-z
21. Moawad EY (2013b) Induction of multiple sclerosis and response to tyrosine kinase inhibitors. Indian J Clin Biochem. doi:10.1007/s12291-013-0387-z
22. Moawad EY (2013c) Growth energy of bacteria and the associated electricity generation in fuel cells. Bioeng Biosci 1:5-10. doi:10.13189/bb. 2013.010102
23. Moawad EY (2013d) Nuclear transmutation and cancer in the biological cell. Int J Biochem Biophys 1:1-8. doi:10.13189/ijbb.2013.010101
24. Moawad EY (2013e) Safe doses and cancer treatment evaluation. Cancer Oncol Res 1:6-11. doi:10.13189/cor.2013.010102
25. Nguyen HQ, Magaret AS, Kitahata MM et al (2008) Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 22:937-945 (Pubitemid 351652244)
26. Pajonk F, Himmelsbach J, Riess K et al (2002) The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62:5230-5235 (Pubitemid 35024595)
27. Pati S, Pelser CB, Dufraine J, Bryant JL, Reitz MS Jr, Weichold FF (2002) Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99(10):3771-3779 (Pubitemid 34534550)
28. Perrin L, Telenti A (1998) HIV treatment failure: testing for HIV resistance in clinical practice. Science 280:1871-1873 (Pubitemid 28299381)
29. Sgadari C et al (2003) Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 4(9):537-547 (Pubitemid 38351710)
30. + T-cells and decreases their susceptibility to apoptosis in vitro [abstract]. Blood 90:2568
31. Sriranga MA, Milani M, Mitra R, Guo Z, Rodriguez M et al (2011) The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin. J Thorac Oncol 6: 661-670
32. Srirangam A, Mitra R, Wang M et al (2006) Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res 12:1883-1896
33. Talmadge JE et al (2007) Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 170(3):793
34. Torre-Cisneros J, Pozo F, Serrano R et al (2000) Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin. AIDS 14:2215-2217
35. Weichold FF, Bryant JL, Pati S et al (1999) HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol 2:261-269 (Pubitemid 30263437)